Clinical Pharmacokinetics

, Volume 45, Issue 1, pp 1–11 | Cite as

Prediction of Cytochrome P450-Mediated Hepatic Drug Clearance in Neonates, Infants and Children

How Accurate Are Available Scaling Methods?
  • Sven BjörkmanEmail author
Current Opinion


Correct dosing of drugs in neonates, infants and children is hampered by a general lack of knowledge about drug disposition in this population. Suggested methods to improve our knowledge without performing conventional full-scale investigations include population pharmacokinetic studies, allometric scaling of drug disposition according to bodyweight and in silico prediction of pharmacokinetics. The last method entails scaling of pharmacokinetic parameters according to age-dependent changes in drug absorption and elimination capacity, plasma protein binding and physiological characteristics of the subjects. Maturation (or ontogeny) of the drug-metabolising part of the cytochrome P450 (CYP) enzyme system is thus an important factor in the calculations for most drugs. The aim of this commentary is to test and critically examine the proposed methods to estimate hepatic clearance (CL) as a function of age (0–20 years), with CYP3A-mediated metabolism as the case in point. Midazolam and alfentanil were used as model drugs.

Allometric scaling failed to predict the CL of midazolam and alfentanil in neonates. Calculations using in vitro findings on CYP maturation gave better estimates for neonates but very divergent ones for older infants and children. This was chiefly due to very different data on CYP3A4/5 ontogeny in three published studies. In the age range where full adult CYP activity per gram of liver could be assumed, allometric scaling and in silico predictions gave similar results. These predictions were also in approximate agreement with clinical data.

The findings with the two model drugs can very probably be generalised to most drugs cleared by CYP-dependent hepatic metabolism. Allometric scaling accounts for development of body size and function but not for the fact that the drug-metabolising capacity of the liver is generally low at birth. The crucial question in the prediction of CL is thus when the activity of the applicable CYP isoform(s) attains adult levels. There are still not enough data on this, particularly when different studies even on the same CYP isoform have given very divergent results. It may also be pointed out that CYP ontogeny is an area where we have at least some information. There are several other important developmental changes about which we know practically nothing. Thus, while allometric scaling is generally unreliable for prediction in neonates and infants, the alternative method of in silico prediction can at present be used only to obtain tentative initial estimates of drug CL. Neither of the methods can be used as a substitute for actual clinical studies.


Midazolam Plasma Protein Binding Alfentanil Microsomal Protein Allometric Scaling 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No special funding was sought or obtained for the writing of this paper. The author has no commercial or financial interest in the drugs used to illustrate the problems.


  1. 1.
    Yaffe S, editor. Rational therapeutics for infants and children: workshop summary. National Academy Press 2000 [online]. Available from URL: [Accessed 2004 Feb 13]
  2. 2.
    Baber N, Pritchard D. Dose estimation for children. Br J Clin Pharmacol 2003; 56: 489–93PubMedCrossRefGoogle Scholar
  3. 3.
    Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157–67PubMedCrossRefGoogle Scholar
  4. 4.
    Strolin Benedetti M, Baltes EL. Drug metabolism and disposition in children. Fundam Clin Pharmacol 2003; 17: 281–99PubMedCrossRefGoogle Scholar
  5. 5.
    Treluyer J-M, Jacqz-Aigrain E, Alvarez F, et al. Expression of CYP2D6 in developing human liver. Eur J Biochem 1991; 202: 583–8PubMedCrossRefGoogle Scholar
  6. 6.
    Vieira I, Sonnier M, Cresteil T. Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur J Biochem 1996; 238: 476–83PubMedCrossRefGoogle Scholar
  7. 7.
    Lacroix D, Sonnier M, Moncion A, et al. Expression of CYP3A in the human liver: evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997; 247: 625–34PubMedCrossRefGoogle Scholar
  8. 8.
    Treluyer J-M, Gueret G, Cheron G, et al. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. Pharmacogenetics 1997; 7: 441–52PubMedCrossRefGoogle Scholar
  9. 9.
    Sonnier M, Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 1998; 251: 893–8PubMedCrossRefGoogle Scholar
  10. 10.
    Stevens JC, Hines RN, Gu C, et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 2003; 307: 573–82PubMedCrossRefGoogle Scholar
  11. 11.
    Koukouritaki SB, Manro JR, Marsh SA, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004; 308: 365–74Google Scholar
  12. 12.
    de Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 37: 485–505PubMedCrossRefGoogle Scholar
  13. 13.
    Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet 2002; 41: 959–98PubMedCrossRefGoogle Scholar
  14. 14.
    Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin Pharmacokinet 2002; 41: 1077–94PubMedCrossRefGoogle Scholar
  15. 15.
    Johnson TN, Sabzghabaee A, Rostami-Hodjegan A, et al. Prediction of age related changes in midazolam clearance in children [abstract]. Br J Clin Pharmacol 2003; 55: 432–3Google Scholar
  16. 16.
    Johnson TN, Rostami-Hodjegan A, Tucker GT. A comparison of methods to predict drug clearance in neonates, infants and children [abstract]. Br J Clin Pharmacol 2004; 57: 677–8Google Scholar
  17. 17.
    Björkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 2005 Jun; 59(6): 691–704PubMedCrossRefGoogle Scholar
  18. 18.
    Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003; 42: 59–98PubMedCrossRefGoogle Scholar
  19. 19.
    Williams JA, Ring BJ, Cantrell VE, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30: 883–91PubMedCrossRefGoogle Scholar
  20. 20.
    Klees TM, Sheffels P, Dale O, et al. Metabolism of alfentanil by cytochrome P4503A (CYP3A) enzymes. Drug Metab Dispos 2005; 33: 303–11PubMedCrossRefGoogle Scholar
  21. 21.
    Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329–32PubMedCrossRefGoogle Scholar
  22. 22.
    Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469–79PubMedCrossRefGoogle Scholar
  23. 23.
    McNamara PJ, Alcorn J. Protein binding predictions in infants. AAPS Pharm Sci 2002; 4(1): E4CrossRefGoogle Scholar
  24. 24.
    Haddad S, Restieri C, Krishnan K. Characterization of agerelated changes in body weight and organ weights from birth to adolescence in humans. J Toxicol Environ Health A 2001; 64: 453–64PubMedCrossRefGoogle Scholar
  25. 25.
    Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995; 275: 1011–8PubMedGoogle Scholar
  26. 26.
    Greenblatt DJ, Abernethy DR, Locniscar A, et al. Effect of age, gender and obesity on midazolam kinetics. Anesthesiology 1984; 61: 27–35PubMedGoogle Scholar
  27. 27.
    Mandema JW, Tuk B, van Steveninck AL, et al. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992; 51: 715–28PubMedCrossRefGoogle Scholar
  28. 28.
    Björkman S, Wada DR, Berling B-M, et al. Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. J Pharm Sci 2001; 90: 1226–41PubMedCrossRefGoogle Scholar
  29. 29.
    Mathews HML, Carson IW, Lyons SM, et al. A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. Br J Anaesth 1988; 61: 302–7PubMedCrossRefGoogle Scholar
  30. 30.
    Jacqz-Aigrain E, Wood C, Robieux I. Pharmacokinetics of midazolam in critically ill neonates. Eur J Clin Pharmacol 1990; 39(2): 191–2PubMedCrossRefGoogle Scholar
  31. 31.
    Burtin P, Jacqz-Aigrain E, Girard P, et al. Population pharmacokinetics of midazolam in neonates. Clin Pharmacol Ther 1994; 56: 615–25PubMedCrossRefGoogle Scholar
  32. 32.
    Reed MD, Rodarte A, Blumer JL, et al. The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J Clin Pharmacol 2001; 41: 1359–69PubMedCrossRefGoogle Scholar
  33. 33.
    de Wildt SN, de Hoog M, Vinks AA, et al. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. Crit Care Med 2003; 31: 1952–8PubMedCrossRefGoogle Scholar
  34. 34.
    Schüttler J, Stoeckel H. Alfentanil (R 39209) ein neues kurzwirkendes Opioid. Pharmakokinetik und erste klinische Erfahrungen. Anaesthesist 1982; 31: 10–4PubMedGoogle Scholar
  35. 35.
    Bovill JG, Sebel PS, Blackburn CL, et al. The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. Anesthesiology 1982; 57: 439–43PubMedCrossRefGoogle Scholar
  36. 36.
    Camu F, Gepts E, Rucquoi M, et al. Pharmacokinetics of alfentanil in man. Anesth Analg 1982; 61: 657–61PubMedCrossRefGoogle Scholar
  37. 37.
    Fragen RJ, Booij LHDJ, Braak GJJ, et al. Pharmacokinetics of the infusion of alfentanil in man. Br J Anaesth 1983; 55: 1077–81PubMedCrossRefGoogle Scholar
  38. 38.
    Helmers H, van Peer A, Woestenborghs R, et al. Alfentanil kinetics in the elderly. Clin Pharmacol Ther 1984; 36: 239–43PubMedCrossRefGoogle Scholar
  39. 39.
    Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age: a simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987; 240: 159–66PubMedGoogle Scholar
  40. 40.
    van Beem H, van Peer A, Gasparini R, et al. Pharmacokinetics of alfentanil during and after a fixed rate infusion. Br J Anaesth 1989; 62: 610–5PubMedCrossRefGoogle Scholar
  41. 41.
    Lemmens HJM, Burm AGL, Hennis PJ, et al. Influence of age on the pharmacokinetics of alfentanil: gender dependence. Clin Pharmacokinet 1990; 19: 416–22PubMedCrossRefGoogle Scholar
  42. 42.
    Goresky GV, Koren G, Sabourin MA, et al. The pharmacokinetics of alfentanil in children. Anesthesiology 1987; 67: 654–9PubMedCrossRefGoogle Scholar
  43. 43.
    Wiest DB, Ohning BL, Garner SS. The disposition of alfentanil in neonates with respiratory distress. Pharmacotherapy 1991; 11: 308–11PubMedGoogle Scholar
  44. 44.
    Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50: 222–39PubMedCrossRefGoogle Scholar
  45. 45.
    Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics?. Clin Pharmacokinet 2002; 41: 329–42PubMedCrossRefGoogle Scholar
  46. 46.
    Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002; 72: 474–89PubMedCrossRefGoogle Scholar
  47. 47.
    Wandel C, Kim R, Wood M, et al. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 2002; 96: 913–20PubMedCrossRefGoogle Scholar
  48. 48.
    Rubio A, Cox C. Sex, age and alfentanil pharmacokinetics [letter]. Clin Pharmacokinet 1991; 21: 81–2PubMedCrossRefGoogle Scholar
  49. 49.
    Power BM, Forbes AM, van Heerden PV, et al. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998; 34: 25–56PubMedCrossRefGoogle Scholar
  50. 50.
    Anderson BJ, McKee AD, Holford NHG. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet 1997; 33: 313–27PubMedCrossRefGoogle Scholar
  51. 51.
    Fahey JT. Developmental aspects of hepatic blood flow. In: Suchy FJ, editor. Liver disease in children. St Louis (MO): Mosby-Year Book Inc, 1994: 31–8Google Scholar
  52. 52.
    Kamdem LK, Meineke I, Koch I, et al. Limited contribution of CYP3A5 to the hepatic 6β-hydroxylation of testosterone. Naunyn Schmiedeberg’s Arch Pharmacol 2004; 370: 71–7CrossRefGoogle Scholar
  53. 53.
    Ono S, Hatanaka T, Miyazawa S, et al. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 1996; 26: 1155–66PubMedCrossRefGoogle Scholar
  54. 54.
    Yang TJ, Shou M, Korzekwa KR, et al. Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochem Pharmacol 1998; 55: 889–96PubMedCrossRefGoogle Scholar
  55. 55.
    Yee GC, Lennon TP, Gmur DJ, et al. Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 1986; 40: 438–43PubMedCrossRefGoogle Scholar
  56. 56.
    Yee GC, McGuire TR, Gmur DJ, et al. Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation. Transplantation 1988; 46: 399–402PubMedCrossRefGoogle Scholar
  57. 57.
    Ginsberg G, Hattis D, Sonawane B. Incorporating pharmacokinetic differences between children and adults in assessing children’s risk to environmental toxicants. Toxicol Appl Pharmacol 2004; 198: 164–83PubMedCrossRefGoogle Scholar
  58. 58.
    Kharasch ED, Russell M, Garton K, et al. Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology 1997; 87: 26–35PubMedCrossRefGoogle Scholar
  59. 59.
    Kharasch ED, Russell M, Mautz D, et al. The role of cytochrome P450 3A4 in alfentanil clearance: implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 1997; 87: 36–50PubMedCrossRefGoogle Scholar
  60. 60.
    Phimmasone S, Kharasch ED. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. Clin Pharmacol Ther 2001; 70: 505–17PubMedCrossRefGoogle Scholar
  61. 61.
    Kharasch ED, Hoffer C, Walker A, et al. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. Clin Pharmacol Ther 2003; 73: 199–208PubMedCrossRefGoogle Scholar
  62. 62.
    Kharasch ED, Walker A, Hoffer C, et al. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther 2004; 76: 452–66PubMedCrossRefGoogle Scholar
  63. 63.
    Meuldermans WEG, Hurkmans RMA, Heykants JJP. Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood. Arch Int Pharmacodyn 1982; 257: 4–19PubMedGoogle Scholar
  64. 64.
    Chauvin M, Lebrault C, Levron JC, et al. Pharmacokinetics of alfentanil in chronic renal failure. Anesth Analg 1987; 66: 53–6PubMedCrossRefGoogle Scholar
  65. 65.
    Hug CC, Burm AGL, de Lange S. Alfentanil pharmacokinetics in cardiac surgical patients. Anesth Analg 1994; 78: 231–9PubMedCrossRefGoogle Scholar
  66. 66.
    Maitre PO, Vozeh S, Heykants J, et al. Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. Anesthesiology 1987; 66: 3–12PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Hospital PharmacyMalmö University HospitalMalmöSweden
  2. 2.Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical BiosciencesUppsala UniversityUppsalaSweden

Personalised recommendations